Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

EA. Bohula, BM. Scirica, SE. Inzucchi, DK. McGuire, AC. Keech, SR. Smith, E. Kanevsky, SA. Murphy, LA. Leiter, JP. Dwyer, R. Corbalan, C. Hamm, L. Kaplan, JC. Nicolau, TO. Ophuis, KK. Ray, M. Ruda, J. Spinar, T. Patel, W. Miao, C. Perdomo, B....

. 2018 ; 392 (10161) : 2269-2279. [pub] 20181004

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012292
E-zdroje Online Plný text

NLK ProQuest Central od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest) od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci

Odkazy

PubMed 30293771
DOI 10.1016/s0140-6736(18)32328-6
Knihovny.cz E-zdroje

BACKGROUND: There is a direct relationship between bodyweight and risk of diabetes. Lorcaserin, a selective serotonin 2C receptor agonist that suppresses appetite, has been shown to facilitate sustained weight loss in obese or overweight patients. We aimed to evaluate the long-term effects of lorcaserin on diabetes prevention and remission. METHODS: In this randomised, double-blind, placebo-controlled trial done in eight countries, we recruited overweight or obese patients (body-mass index ≥27 kg/m2) with or at high risk for atherosclerotic vascular disease. Eligible patients were aged 40 years or older; patients at high risk for atherosclerotic vascular disease had to be aged 50 years or older with diabetes and at least one other risk factor. Patients were randomly assigned to receive either lorcaserin (10 mg twice daily) or matching placebo. Additionally, all patients had access to a standardised weight management programme based on lifestyle modification. The prespecified primary metabolic efficacy endpoint of time to incident diabetes was assessed in patients with prediabetes at baseline. The prespecified secondary outcomes for efficacy were incident diabetes in all patients without diabetes, achievement of normoglycaemia in patients with prediabetes, and change in glycated haemoglobin (HbA1c) in patients with diabetes. Hypoglycaemia was a prespecified safety outcome. Analysis was by intention to treat, using Cox proportional hazard models for time-to-event analyses. This trial is registered with ClinicalTrials.gov, number NCT02019264. FINDINGS: Between Feb 7, 2014, and Nov 20, 2015, 12 000 patients were randomly assigned to lorcaserin or placebo (6000 patients in each group) and followed up for a median of 3·3 years (IQR 3·0-3·5). At baseline, 6816 patients (56·8%) had diabetes, 3991 (33·3%) prediabetes, and 1193 (9·9%) normoglycaemia. At 1 year, patients treated with lorcaserin had a net weight loss beyond placebo of 2·6 kg (95% CI 2·3-2·9) for those with diabetes, 2·8 kg (2·5-3·2) for those with prediabetes, and 3·3 kg (2·6-4·0) for those with normoglycaemia (p<0·0001 for all analyses). Lorcaserin reduced the risk of incident diabetes by 19% in patients with prediabetes (172 [8·5%] of 2015 vs 204 [10·3%] of 1976; hazard ratio 0·81, 95% CI 0·66-0·99; p=0·038) and by 23% in patients without diabetes (174 [6·7%] of 2615 vs 215 [8·4%] of 2569; 0·77, 0·63-0·94; p=0·012). Lorcaserin resulted in a non-significant increase in the rate of achievement of normoglycaemia in patients with prediabetes (185 [9·2%] vs 151 [7·6%]; 1·20, 0·97-1·49; p=0·093). In patients with diabetes, lorcaserin resulted in a reduction of 0·33% (95% CI 0·29-0·38; p<0·0001) in HbA1c compared with placebo at 1 year from a mean baseline of 53 mmol/mol (7·0%). In patients with diabetes at baseline, severe hypoglycaemia with serious complications was rare, but more common with lorcaserin (12 [0·4%] vs four [0·1%] events; p=0·054). INTERPRETATION: Lorcaserin decreases risk for incident diabetes, induces remission of hyperglycaemia, and reduces the risk of microvascular complications in obese and overweight patients, supporting the role of lorcaserin as an adjunct to lifestyle modification for chronic management of weight and metabolic health. FUNDING: Eisai.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012292
003      
CZ-PrNML
005      
20190415134636.0
007      
ta
008      
190405s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(18)32328-6 $2 doi
035    __
$a (PubMed)30293771
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bohula, Erin A $u TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: ebohula11@bwh.harvard.edu.
245    10
$a Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial / $c EA. Bohula, BM. Scirica, SE. Inzucchi, DK. McGuire, AC. Keech, SR. Smith, E. Kanevsky, SA. Murphy, LA. Leiter, JP. Dwyer, R. Corbalan, C. Hamm, L. Kaplan, JC. Nicolau, TO. Ophuis, KK. Ray, M. Ruda, J. Spinar, T. Patel, W. Miao, C. Perdomo, B. Francis, S. Dhadda, MP. Bonaca, CT. Ruff, MS. Sabatine, SD. Wiviott, . ,
520    9_
$a BACKGROUND: There is a direct relationship between bodyweight and risk of diabetes. Lorcaserin, a selective serotonin 2C receptor agonist that suppresses appetite, has been shown to facilitate sustained weight loss in obese or overweight patients. We aimed to evaluate the long-term effects of lorcaserin on diabetes prevention and remission. METHODS: In this randomised, double-blind, placebo-controlled trial done in eight countries, we recruited overweight or obese patients (body-mass index ≥27 kg/m2) with or at high risk for atherosclerotic vascular disease. Eligible patients were aged 40 years or older; patients at high risk for atherosclerotic vascular disease had to be aged 50 years or older with diabetes and at least one other risk factor. Patients were randomly assigned to receive either lorcaserin (10 mg twice daily) or matching placebo. Additionally, all patients had access to a standardised weight management programme based on lifestyle modification. The prespecified primary metabolic efficacy endpoint of time to incident diabetes was assessed in patients with prediabetes at baseline. The prespecified secondary outcomes for efficacy were incident diabetes in all patients without diabetes, achievement of normoglycaemia in patients with prediabetes, and change in glycated haemoglobin (HbA1c) in patients with diabetes. Hypoglycaemia was a prespecified safety outcome. Analysis was by intention to treat, using Cox proportional hazard models for time-to-event analyses. This trial is registered with ClinicalTrials.gov, number NCT02019264. FINDINGS: Between Feb 7, 2014, and Nov 20, 2015, 12 000 patients were randomly assigned to lorcaserin or placebo (6000 patients in each group) and followed up for a median of 3·3 years (IQR 3·0-3·5). At baseline, 6816 patients (56·8%) had diabetes, 3991 (33·3%) prediabetes, and 1193 (9·9%) normoglycaemia. At 1 year, patients treated with lorcaserin had a net weight loss beyond placebo of 2·6 kg (95% CI 2·3-2·9) for those with diabetes, 2·8 kg (2·5-3·2) for those with prediabetes, and 3·3 kg (2·6-4·0) for those with normoglycaemia (p<0·0001 for all analyses). Lorcaserin reduced the risk of incident diabetes by 19% in patients with prediabetes (172 [8·5%] of 2015 vs 204 [10·3%] of 1976; hazard ratio 0·81, 95% CI 0·66-0·99; p=0·038) and by 23% in patients without diabetes (174 [6·7%] of 2615 vs 215 [8·4%] of 2569; 0·77, 0·63-0·94; p=0·012). Lorcaserin resulted in a non-significant increase in the rate of achievement of normoglycaemia in patients with prediabetes (185 [9·2%] vs 151 [7·6%]; 1·20, 0·97-1·49; p=0·093). In patients with diabetes, lorcaserin resulted in a reduction of 0·33% (95% CI 0·29-0·38; p<0·0001) in HbA1c compared with placebo at 1 year from a mean baseline of 53 mmol/mol (7·0%). In patients with diabetes at baseline, severe hypoglycaemia with serious complications was rare, but more common with lorcaserin (12 [0·4%] vs four [0·1%] events; p=0·054). INTERPRETATION: Lorcaserin decreases risk for incident diabetes, induces remission of hyperglycaemia, and reduces the risk of microvascular complications in obese and overweight patients, supporting the role of lorcaserin as an adjunct to lifestyle modification for chronic management of weight and metabolic health. FUNDING: Eisai.
650    _2
$a senioři $7 D000368
650    _2
$a anorektika $x terapeutické užití $7 D001067
650    _2
$a ateroskleróza $x komplikace $x farmakoterapie $7 D050197
650    _2
$a benzazepiny $x terapeutické užití $7 D001552
650    _2
$a tělesná hmotnost $x účinky léků $7 D001835
650    _2
$a diabetes mellitus 2. typu $x krev $x komplikace $x farmakoterapie $x prevence a kontrola $7 D003924
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glykovaný hemoglobin $x analýza $7 D006442
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x terapeutické užití $7 D007004
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a obezita $x komplikace $7 D009765
650    _2
$a nadváha $x komplikace $7 D050177
650    _2
$a prediabetes $x komplikace $x farmakoterapie $x prevence a kontrola $7 D011236
650    _2
$a indukce remise $7 D012074
650    _2
$a hmotnostní úbytek $x účinky léků $7 D015431
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Scirica, Benjamin M $u TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
700    1_
$a Inzucchi, Silvio E $u Section of Endocrinology, Yale School of Medicine, New Haven, CT, USA.
700    1_
$a McGuire, Darren K $u Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
700    1_
$a Keech, Anthony C $u NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
700    1_
$a Smith, Steven R $u Translational Research Institute for Metabolism and Diabetes, Florida Hospital, Orlando, FL, USA.
700    1_
$a Kanevsky, Estella $u TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
700    1_
$a Murphy, Sabina A $u TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
700    1_
$a Leiter, Lawrence A $u Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
700    1_
$a Dwyer, Jamie P $u Division of Nephrology/Hypertension, Vanderbilt University Medical Center, Nashville, TN, USA.
700    1_
$a Corbalan, Ramon $u Department of Cardiovascular Diseases, Catholic University School of Medicine, Santiago, Chile.
700    1_
$a Hamm, Christian $u The Kerchoff Heart Center, Bad Bauheim, Germany.
700    1_
$a Kaplan, Lee $u Obesity, Metabolism and Nutrition Institute, Massachusetts General Hospital, Boston, MA, USA.
700    1_
$a Nicolau, Jose Carlos $u Heart Institute, University of São Paulo, São Paulo, Brazil.
700    1_
$a Ophuis, Ton Oude $u CWZ Hospital, Nijmegen, Netherlands.
700    1_
$a Ray, Kausik K $u Imperial Centre for Cardiovascular Disease Prevention, School of Public Health, Imperial College London, London, UK.
700    1_
$a Ruda, Mikhail $u Russian Cardiologic Research and Production Complex of Rosmedtechnology, Moscow, Russia.
700    1_
$a Spinar, Jindrich $u Internal Cardiology Department, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Patel, Tushar $u Eisai, Woodcliff Lake, NJ, USA.
700    1_
$a Miao, Wenfeng $u Eisai, Woodcliff Lake, NJ, USA.
700    1_
$a Perdomo, Carlos $u Eisai, Woodcliff Lake, NJ, USA.
700    1_
$a Francis, Bruce $u Eisai, Woodcliff Lake, NJ, USA.
700    1_
$a Dhadda, Shobha $u Eisai, Woodcliff Lake, NJ, USA.
700    1_
$a Bonaca, Marc P $u TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
700    1_
$a Ruff, Christian T $u TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
700    1_
$a Sabatine, Marc S $u TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
700    1_
$a Wiviott, Stephen D $u TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
700    1_
$a ,
773    0_
$w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 392, č. 10161 (2018), s. 2269-2279
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30293771 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190415134659 $b ABA008
999    __
$a ok $b bmc $g 1391602 $s 1050597
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 392 $c 10161 $d 2269-2279 $e 20181004 $i 1474-547X $m Lancet $n Lancet $x MED00010161
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace